



## Press release |

### IBA selected for a new Proton Therapy Center in Dresden, Germany

***IBA reinforces its leadership in particle therapy by signing a contract with the Universitätsklinikum Carl Gustav Carus for the installation of a new clinical proton therapy system in Germany. In Dresden, IBA signed the 10<sup>th</sup> contract to install a particle therapy facility in Europe.***

**Louvain-la-Neuve, Belgium, January 17th, 2010** – IBA (Ion Beam Applications S.A.) announced that the Universitätsklinikum Carl Gustav Carus from the Dresden Technical University, Germany, has selected IBA for the installation of a proton therapy facility.

Further to a European public tender, the Dresden Technical University has selected IBA for the supply and installation of a proton therapy facility, including a gantry-equipped treatment room and a research room. The agreement also includes a long term maintenance contract.

The Universitätsklinikum Carl Gustav Carus is a leading research center with very advanced research in particle physics and radiation therapy. It is among others developing laser beam technology that may be used for future development of proton therapy. Their need for a “gold standard” accelerator against which to benchmark their new development naturally led them to select the IBA system.

*“We are proud to be selected by the Universitätsklinikum Carl Gustav Carus especially since both institutions plan to develop a joint R&D program that aims to develop proton therapy. We are honored to take part in this important project”,* said Pierre Mottet, Chief Executive Officer of IBA. *“We are particularly excited as this new center will participate to make proton therapy more accessible to more patients across Europe”* he added.

IBA is committed to making proton therapy, the most accurate cancer treatment, available worldwide. To date, IBA has been selected to install 24 proton therapy centers of which 11 are treating patients and 7 are under construction. This represents altogether more than half of the clinical-based proton therapy facilities in the world.

Proton therapy is increasingly considered the best radiotherapy for cancer due to its superior dose distribution. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and, even better, spare healthy surrounding tissues. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving outcome and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.



## Press release |

### **ABOUT IBA**

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. *Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.*(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### Contact

#### **IBA**

#### **Jean-Marc Bothy**

Chief Financial Officer

Phone: +32 10 47 58 90

Email : [InvestorRelations@iba-group.com](mailto:InvestorRelations@iba-group.com)

#### **IBA**

#### **Sandrine Leriche**

VP Corporate Communication

Phone: +32 10 47 58 90

Email : [Sandrine.leriche@iba-group.com](mailto:Sandrine.leriche@iba-group.com)